Lataa...
One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders
PURPOSE: A sub-population of patients with diabetic macular edema (DME) responds less effectively to off-label use of Bevacizumab. Approval of Aflibercept for DME has offered Bevacizumab nonresponders an alternative therapeutic option. Herein, we investigate the anatomical and functional changes ass...
Tallennettuna:
| Julkaisussa: | Indian J Ophthalmol |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Wolters Kluwer - Medknow
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7933844/ https://ncbi.nlm.nih.gov/pubmed/33463593 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/ijo.IJO_459_20 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|